SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

How do GLP‑1 receptor agonists and SGLT‑2 inhibitors compare for cardiovascular and renal protection in type 2 diabetes?

Both GLP‑1 receptor agonists (GLP‑1 RAs) and SGLT‑2 inhibitors reduce cardiovascular and kidney risk in people with type 2 diabetes, but they do so with different strengths: GLP‑1 RAs show consistent ...